Tumor Biology

, Volume 35, Issue 7, pp 7275–7282 | Cite as

Expression of basic fibroblast growth factor, CD31, and α-smooth muscle actin and esophageal cancer recurrence after definitive chemoradiation

  • Yongshun ChenEmail author
  • Xiaohong Li
  • Haijun Yang
  • Yubing Xia
  • Leiming Guo
  • Xiaoyuan Wu
  • Chunyu He
  • You Lu
Research Article


There is cumulative evidence that stromal reaction in cancer has an important diagnostic and prognostic significance. The aims of this study were to analyze the expression of basic fibroblast growth factor (FGF-2), CD31, and α-smooth muscle actin (SMA) in esophageal cancer patients and to establish their significance as indicators of disease recurrence after definitive chemoradiation (CRT). Protein expressions of FGF-2, CD31, and SMA were evaluated by immunohistochemistry and Western blot analysis in 70 patients, 20 with esophageal squamous cell carcinoma (ESCC) and 50 with locally recurrent ESCC after definitive CRT. Twenty matched normal esophageal squamous epithelium were also studied as controls. Esophageal cancer tissues showed positive expression of FGF-2, CD31, and SMA; in contrast, FGF-2 expression was not detected and only little staining for CD31 and SMA was noted in normal epithelium. Protein levels of FGF-2, CD31, and SMA were significantly elevated in recurrent ESCC. Among the patients with locally recurrent disease, expression of FGF-2 and SMA was notably high in whom the tumor recurred locally within 24 months after definitive CRT. The 2- and 5-year local recurrence-free survival rate was 15.4 % and 0 in patients with high FGF-2 expression, compared with 45.8 and 33.3 % in those who expressed low FGF-2, respectively (P = 0.005). Of patients who expressed high SMA, the 2- and 5-year local recurrence-free survival rate was 21.7 and 8.7 %, respectively, compared to those with low SMA expression which was 37.0 and 22.2 %, respectively (P = 0.016). Overexpression of FGF-2 and SMA is associated with local recurrence and reduced recurrence-free survival after definitive CRT for ESCC. The data also suggest that targeting stromal cells may be an attractive approach for esophageal cancer therapy strategies.


Basic fibroblast growth factor CD31 α-smooth muscle actin Chemoradiation Esophageal cancer Recurrence 



This work was supported by a grant-in-aid from the National Natural Science Foundation of China (No: U1204816) and Henan Provincial Science and Technology Bureau.

Conflicts of interest



  1. 1.
    Bremnes RM, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6:209–17.CrossRefPubMedGoogle Scholar
  2. 2.
    Noma K, Smalley KS, Lioni M, Naomoto Y, Tanaka N, El-Deiry W, et al. The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology. 2008;134:1981–93.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Xu Z, Wang S, Wu M, Zeng W, Wang X, Dong Z. TGFβ1 and HGF protein secretion by esophageal squamous epithelial cells and stromal fibroblasts in oesophageal carcinogenesis. Oncol Lett. 2013;6:401–6.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Barclay C, Li AW, Geldenhuys L, Baguma-Nibasheka M, Porter GA, Veugelers PJ, et al. Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene. Clin Cancer Res. 2005;11:7683–91.CrossRefPubMedGoogle Scholar
  5. 5.
    Erez N, Truitt M, Olson P, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappa B-dependent manner. Cancer Cell. 2010;17:135–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401.CrossRefPubMedGoogle Scholar
  7. 7.
    Hoff PM, Machado KK. Role of angiogenesis in the pathogenesis of cancer. Cancer Treat Rev. 2012;38:825–33.CrossRefPubMedGoogle Scholar
  8. 8.
    GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. GLOBOCAN. IARC. 2013.Google Scholar
  9. 9.
    Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou X, et al. Esophageal cancer incidence and mortality in China, 2009. J Thorac Dis. 2013;5:19–26.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Shridhar R, Almhanna K, Meredith KL, Biagioli MC, Chuong MD, Cruz A, et al. Radiation therapy and esophageal cancer. Cancer Control. 2013;20:97–110.PubMedGoogle Scholar
  11. 11.
    Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012;118:2632–40.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Wolff C, Schott C, Porschewski P, Reischauer B, Becker KF. Successful protein extraction from over-fixed and long-term stored formalin-fixed tissues. PLoS ONE. 2011;6:e16353.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Chen Y, Lu Y, Wang Y, Yang H, Xia Y, Chen M, et al. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone. Dis Esophagus. 2014;27:134–40.CrossRefPubMedGoogle Scholar
  14. 14.
    Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9:665–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Murphy PR, Sato Y, Knee R. Phosphorothioate antisense oligonucleotides against basic fibroblast growth factor inhibit anchorage-dependent and anchorage independent growth of a malignant glioblastoma cell line. Mol Endocrinol. 1992;6:877–84.PubMedGoogle Scholar
  16. 16.
    Carmo CR, Lyons-Lewis J, Seckl MJ, Costa-Pereira AP. A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells. PLoS ONE. 2011;6:e19861.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Miyake H, Hara I, Gohji K, Yoshimura K, Arakawa S, Kamidono S. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett. 1998;30:121–6.CrossRefGoogle Scholar
  18. 18.
    Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9:193–9.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Kozin SV, Duda DG, Munn LL, Jain RK. Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors? J Natl Cancer Inst. 2012;104:899–905.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem. 2007;101:805–15.CrossRefPubMedGoogle Scholar
  21. 21.
    Tsujino T, Seshimo I, Yamamoto H, Ngan CY, Ezumi K, Take- masa I, et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res. 2007;13:2082–90.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yongshun Chen
    • 1
    • 2
    Email author
  • Xiaohong Li
    • 3
  • Haijun Yang
    • 4
  • Yubing Xia
    • 5
  • Leiming Guo
    • 2
  • Xiaoyuan Wu
    • 2
  • Chunyu He
    • 2
  • You Lu
    • 1
  1. 1.Division of Thoracic Oncology, West China Hospital, Cancer Center, West China School of Clinical MedicineSichuan UniversityChengduChina
  2. 2.Department of Radiation OncologyZhengzhou University Affiliated Cancer Hospital, Henan Cancer HospitalZhengzhouChina
  3. 3.Department of PathologyZhengzhou University Affiliated Cancer Hospital, Henan Cancer HospitalZhengzhouChina
  4. 4.Department of PathologyAnyang Cancer HospitalAnyangChina
  5. 5.Department of Medical OncologyKaifeng Cancer HospitalKaifengChina

Personalised recommendations